PTLA News and Press, Portola Pharmaceuticals Inc. From 10/03/19

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad-hoc quer...

The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with this Read more ...

SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love , M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of experience in the discovery...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla Inc. pose as an investment?" In an ad hoc quer...

SOUTH SAN FRANCISCO, Calif. , Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In addition, the underwriter...

Portola Pharmaceuticals (NASDAQ:PTLA) today announced that it would offer $200 million USD of its common stock in an underwritten public offering. PTLA stock fell 1.7% to $30.11 off the back of the announcement. PTLA Stock Offering Portola is a San Francisco-based pharmaceuticals c...

Portola Pharmaceuticals (NASDAQ: PTLA ) is down 4.8% after filing to offer $200M in common shares. More news on: Portola Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SOUTH SAN FRANCISCO, Calif. , Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA)  today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The company expects to...

Portola Pharmaceuticals, Inc. (PTLA) Q2 2019 Earnings Conference Call August 07, 2019 4:30 PM ET Company Participants Cara Miller - Vice President of Investor Relations & Corporate Communications Scott Garland - President & Chief Executive Officer Mardi Dier - Chief Finan...

The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...